Demonstrates the impact of tumor burden on survival in rare cancers, highlighting improvement opportunities in treatment.
Baseline tumor burden is a powerful, tumor‐agnostic, prognostic marker across rare cancers, and patients with greater disease volume at treatment initiation face significantly worse survival, independent of cancer type. Critically, tumor burden predicts prognosis rather than immunotherapy response, underscoring that earlier diagnosis and earlier line intervention remain the most consequential opportunities to improve outcomes in rare malignancies.
No takes yet. Share an insight, caveat, or question.
Subbiah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: